Pablo Okhuysen, MD, FACP from MD Anderson speaks about the ASCO 2021 Abstract – Impact of Cancer-Related Diarrhea on Changes in Cancer Therapy Patterns: Real World Evidence.
Napo Pharmaceuticals, Inc., Jaguar’s wholly owned subsidiary, and Napo’s partners have had their abstract on patient results consistent with cancer therapy-related diarrhea (“CTD”) approved for poster presentation at the American Society of Clinical Oncology (ASCO®) Annual Meeting, which will be held digitally from June 4-8, 2021.
The approved poster presentation’s title is:
Real-world research on the effect of cancer-related diarrhea on improvements in cancer therapy trends
Symptoms and Survivorship (Poster Session)
Pablo C. Okhuysen, MD, is the study’s lead scientist. Dr. Okhuysen is a professor of medicine at the University of Texas MD Anderson Cancer Center in Houston, Texas, in the Department of Infectious Diseases, Infection Control, and Employee Health, Division of Internal Medicine. Lee Schwartzberg, MD, FACP, a noted medical oncologist and hematologist who serves as Executive Director of West Cancer Center in Memphis, Tennessee, and Eric Roeland, MD, FAAHPM, Attending Physician, Harvard Medical School’s Center for Palliative Care, are among the other reporters. Napo employs all three contributors as primary opinion figures and advisors.
For the 2021 ASCO Annual Meeting, ASCO received over 5,400 abstracts, which were approved by the Society’s Scientific Program Committee and ASCO Leadership. The ASCO website has more detail about the 2021 ASCO Annual Meeting: https://meetings.asco.org/am/attend.
Napo’s pivotal Phase 3 clinical trial of crofelemer (Mytesi®) for prophylaxis of diarrhea in adult cancer patients undergoing targeted therapy began in October 2020 and is still underway, as previously announced.